NY-REN-34 inhibitors are a class of chemical compounds designed to target and inhibit the activity of the NY-REN-34 protein, a molecule often associated with specific cellular functions. These inhibitors are typically small molecules that interfere with the active sites or regulatory domains of the NY-REN-34 protein, thereby blocking its normal biochemical activity. Structurally, NY-REN-34 inhibitors can vary widely, but they often share common features that allow them to bind specifically to the protein's functional motifs. This selectivity is crucial, as it enables them to exert their effect on NY-REN-34 without significantly affecting other proteins or cellular pathways. The development of these inhibitors relies heavily on structure-activity relationship (SAR) studies to optimize binding affinity and specificity, and advanced techniques like high-throughput screening and molecular docking are employed to identify promising candidates from large chemical libraries.
The mechanisms of action of NY-REN-34 inhibitors are diverse, depending on the inhibitor's mode of binding and interaction with the protein. Some inhibitors are competitive, directly competing with the substrate for binding to the active site, while others are allosteric, binding to a different region of the protein to induce conformational changes that reduce its activity. Understanding the conformational dynamics of NY-REN-34 is essential for designing effective inhibitors that can alter its functional state. The chemical scaffolds of these inhibitors often include heterocyclic cores, aromatic rings, and substituents that enhance hydrophobic or hydrogen-bonding interactions with the NY-REN-34 protein. Moreover, the physicochemical properties of these inhibitors, such as solubility, stability, and cell permeability, are carefully considered during their design and synthesis to ensure efficient modulation of the NY-REN-34 protein in a biological context. As a result, the development of NY-REN-34 inhibitors is a multidisciplinary effort involving organic chemistry, structural biology, and enzymology to understand and effectively target the protein.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
May demethylate the promoter of NY-REN-34, potentially influencing expression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Could affect DNA methylation status, possibly influencing NY-REN-34 expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Histone deacetylase inhibitor that might affect NY-REN-34 expression. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
HDAC inhibitor that could potentially influence chromatin structure and NY-REN-34 expression. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
May influence histone acetylation and potentially NY-REN-34 expression. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Could affect histone modification and possibly the expression of NY-REN-34. | ||||||
ITF2357 | 732302-99-7 | sc-364513 sc-364513A | 5 mg 50 mg | $340.00 $1950.00 | ||
Might affect chromatin remodeling and influence NY-REN-34 expression. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Could influence histone modification states and NY-REN-34 expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Affects histone acetylation and potentially NY-REN-34 expression. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
Bromodomain inhibitor that might influence transcription factors affecting NY-REN-34 expression. | ||||||